{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T16:27:27Z","timestamp":1777739247957,"version":"3.51.4"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T00:00:00Z","timestamp":1531785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jcrsjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.jcrs.2018.06.056","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T06:24:00Z","timestamp":1536128640000},"page":"1220-1229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery"],"prefix":"10.1097","volume":"44","author":[{"given":"Raymond","family":"Fong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce E.","family":"Silverstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H.","family":"Peace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon I.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason L.","family":"Vittitow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R3-10-20210219","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00002018-200225010-00004","article-title":"Locally administered ocular corticosteroids; benefits and risks.","volume":"25","author":"McGhee","year":"2002","journal-title":"Drug Saf"},{"key":"R4-10-20210219","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/jop.2006.0067","article-title":"The etiology of steroid cataract.","volume":"23","author":"James","year":"2007","journal-title":"J Ocular Pharm Ther"},{"key":"R8-10-20210219","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jcrs.2012.10.039","article-title":"Loteprednol etabonate 0.5 versus prednisolone acetate 1.0 for the treatment of inflammation after cataract surgery.","volume":"39","author":"Lane","year":"2013","journal-title":"J Cataract Refract Surg"},{"key":"R11-10-20210219","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s12325-013-0059-7","article-title":"Loteprednol etabonate ophthalmic gel 0.5 following cataract surgery: integrated analysis of two clinical studies.","volume":"30","author":"Rajpal","year":"2013","journal-title":"Adv Ther"},{"key":"R12-10-20210219","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jcrs.2012.09.013","article-title":"Efficacy and safety of loteprednol etabonate 0.5 gel in the treatment of ocular inflammation and pain after cataract surgery.","volume":"39","author":"Rajpal","year":"2013","journal-title":"J Cataract Refract Surg"},{"key":"R16-10-20210219","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/ICO.0000000000000475","article-title":"Loteprednol etabonate 0.5 gel vs. prednisolone acetate 1 solution after Descemet membrane keratoplasty: prospective randomized trial.","volume":"34","author":"Price","year":"2015","journal-title":"Cornea"},{"key":"R19-10-20210219","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcrs.2008.09.024","article-title":", the Difluprednate Ophthalmic Emulsion 0.05 (Durezol) Study Group. Difluprednate ophthalmic emulsion 0.05 for postoperative inflammation and pain.","volume":"35","author":"Korenfeld","year":"2009","journal-title":"J Cataract Refract Surg"},{"key":"R24-10-20210219","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","article-title":"Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use.","volume":"144","author":"Robin","year":"2007","journal-title":"Am J Ophthalmol"}],"container-title":["Journal of Cataract and Refractive Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0886335018305935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0886335018305935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1016\/j.jcrs.2018.06.056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T18:33:52Z","timestamp":1623782032000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/02158034-201810000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1016\/j.jcrs.2018.06.056","relation":{},"ISSN":["0886-3350"],"issn-type":[{"value":"0886-3350","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery","name":"articletitle","label":"Article Title"},{"value":"Journal of Cataract & Refractive Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcrs.2018.06.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc. on behalf of ASCRS and ESCRS.","name":"copyright","label":"Copyright"}]}}